Evidence map›Paper›PMID 39313857›Full record

Trial reportHuman vaccines & immunotherapeutics2024

Immunogenicity and safety of an inactivated COVID-19 vaccine (CoronaVac®) co-administered with an inactivated enterovirus type 71 vaccine (Inlive®): A phase 4, randomized, controlled trial.

Yajun Shu, Zhuoqun Sun, Fan Gao, Zhuhang Huang, Xing Meng, Shaomin Chen, Qun Shu, Lianhao Wang, Hengming Zhang, Zhifang Ying and 1 more

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase IV
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04993365 (A Randomized and Controlled Ⅳ Clinical Trial to Evaluate the Immunogenicity and Safety of COVID-19 Vaccine), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04993365 phase4completednot on this map

A Randomized and Controlled Ⅳ Clinical Trial to Evaluate the Immunogenicity and Safety of COVID-19 Vaccine (Vero Cell), Inactivated Co-administrated With EV71 Vaccine (Vero Cell) in Children Aged 3-5 Years Old

TypeinterventionalSponsorSinovac Research and Development Co., Ltd.Ran2021 to 2022Enrolled520ConditionsCOVID-19ArmsExperimental Group, Control Group
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yajun ShuDepartment of Biological Products Monitoring and Evaluation, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, China.
Zhuoqun SunDepartment of Clinical Research and Development, Sinovac Life Sciences Co., Ltd, Beijing, China.
Fan GaoDivision of Vaccines, National Institutes for Food and Drug Control, Beijing, China.
Zhuhang HuangDepartment of Biological Products Monitoring and Evaluation, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, China.
Xing MengDepartment of Clinical Research and Development, Sinovac Biotech Co., Ltd, Beijing, China.
Shaomin ChenDepartment of Biological Products Monitoring and Evaluation, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, China.
Qun ShuDepartment of Statistics Sciences, Beijing KeyTech Statistical Consulting Co., Ltd, Beijing, China.
Lianhao WangDepartment of Clinical Research and Development, Sinovac Life Sciences Co., Ltd, Beijing, China.
Hengming ZhangDepartment of Clinical Research and Development, Sinovac Biotech Co., Ltd, Beijing, China.
Zhifang YingDivision of Vaccines, National Institutes for Food and Drug Control, Beijing, China.
Jikai ZhangDepartment of Biological Products Monitoring and Evaluation, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

trial registration numberNCT04993365 (ClinicalTrials.gov).

Indexed as

Antibodies, ViralCOVID-19COVID-19 VaccinesImmunogenicity, VaccineVaccines, InactivatedAdultEnterovirus A, HumanFemaleHumansMaleMiddle AgedSARS-CoV-2Vaccines, CombinedYoung AdultAntibodies, ViralCOVID-19 VaccinesSARS-CoV-2 inactivated vaccinessinovac COVID-19 vaccineVaccines, CombinedVaccines, InactivatedchildrenCo-administrationimmunogenicityinactivated COVID-19 vaccineinactivated EV71 vaccinesafety

Identifiers

PMID39313857
PMCPMC11423659

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.